6-Bromo-5-chloropyridin-2-amine | CAS:1004294-58-9

We serve 6-Bromo-5-chloropyridin-2-amine CAS:1004294-58-9 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.
6-Bromo-5-chloropyridin-2-amine

Chemical Name: 6-Bromo-5-chloropyridin-2-amine
CAS.NO:1004294-58-9
Synonyms:6-Bromo-5-chloropyridin-2-amine
Molecular Formula:C5H4BrClN2
Molecular Weight:207.45600
 
Physical and Chemical Properties:
Density:1.834
 
Specification:
Appearance:White solid
Purity:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Preserve in well-closed, light-resistant and airtight containers
Application: Pesticide intermediates, dye intermediates, flavor and fragrance intermediates, pharmaceutical intermediates



Contact us for information like 6-Bromo-5-chloropyridin-2-amine chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,6-Bromo-5-chloropyridin-2-amine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,6-Bromo-5-chloropyridin-2-amine Use and application,6-Bromo-5-chloropyridin-2-amine technical grade,usp/ep/jp grade.


Related News: Speaking to Sky News, Raab said he could not confirm the “precise number” of those arriving into the UK on Sunday.Methyl 4-bromobutyrate manufacturer The first case of the 2019 novel coronavirus in Massachusetts has been confirmed in a man returning from Wuhan, China who is in his 20s and lives in Boston. The Massachusetts Department of Public Health (DPH) and the Boston Public Health Commission (BPHC) were notified by the US Centers for Disease Control and Prevention (CDC) of the positive test results late Friday evening. This is the eighth case of infection with 2019 novel coronavirus reported in the United States. The risk to the public from the 2019 novel coronavirus remains low in Massachusetts.2-Chloro-3-methyl-5-nitropyridine supplier The cell product candidate is being developed under a collaboration with Memorial Sloan Kettering Cancer Center (MSK) led by Michel Sadelain, MD, PhD.4,6-Dichloro-2-(propylthio)pyrimidin-5-amine vendor A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA’s concerns.A GSK spokesman said it was not yet clear by when ViiV would be able to address the FDA’s concerns.